CSIMarket
 


Cogent Biosciences Inc   (COGT)
Other Ticker:  
 

Cogent Biosciences Inc 's Working Capital Ratio

COGT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 8.24 below Cogent Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 145 other companies have achieved higher Working Capital Ratio than Cogent Biosciences Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 204 to 517.

Explain Working Capital Ratio
How much in Current Assets COGTīs has?
What is the value of COGTīs Current Liabilities?


COGT Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 47.42 % -6.87 % 18.13 % 57.22 % 40.95 %
Y / Y Current Assets Change -3.53 % 1.16 % 16.19 % 19.01 % 42.85 %
Working Capital Ratio MRQ 8.24 12.99 10.71 9.87 12.59
COGT's Total Ranking # 517 # 204 # 440 # 484 # 448
Seq. Current Liabilities Change 34.79 % 21.96 % -21.34 % 14 % -14.85 %
Seq. Current Assets Change -14.52 % 47.84 % -14.6 % -10.61 % -10.36 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 246
Overall Market # 517


Working Capital Ratio Statistics
High Average Low
53.33 10.91 1.53
(Dec 31 2018)   (Mar 31 2018)




Financial Statements
Cogent Biosciences Inc 's Current Liabilities $ 35 Millions Visit COGT's Balance sheet
Cogent Biosciences Inc 's Current Assets $ 286 Millions Visit COGT's Balance sheet
Source of COGT's Sales Visit COGT's Sales by Geography


Cumulative Cogent Biosciences Inc 's Working Capital Ratio

COGT's Working Capital Ratio for the trailling 12 Months

COGT Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 47.42 % -6.87 % 18.13 % 57.22 % 40.95 %
Y / Y Current Assets TTM Growth -3.53 % 1.16 % 16.19 % 19.01 % 42.85 %
Working Capital Ratio TTM 10.25 11.54 11.28 11.33 12.12
Total Ranking TTM # 263 # 251 # 294 # 342 # 344
Seq. Current Liabilities TTM Growth 34.79 % 21.96 % -21.34 % 14 % -14.85 %
Seq. Current Assets TTM Growth -14.52 % 47.84 % -14.6 % -10.61 % -10.36 %


On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $34.72 millions, cumulative Working Capital Ratio decreased to 10.25 above the COGT average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 489 other companies have achieved higher Working Capital Ratio than Cogent Biosciences Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3548 to 3600.

Explain Working Capital Ratio
How much in Current Assets COGTīs has?
What is the value of COGTīs Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 490
Healthcare Sector # 1011
Within the Market # 517


trailing twelve months Working Capital Ratio Statistics
High Average Low
17.51 8.71 2.46
(Sep 30 2021)   (Dec 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Terns Pharmaceuticals Inc   22.38 $ 270.455  Millions$ 12.087  Millions
Tyra Biosciences Inc   22.14 $ 224.630  Millions$ 10.147  Millions
Cyteir Therapeutics Inc   21.89 $ 130.643  Millions$ 5.969  Millions
Ars Pharmaceuticals Inc   21.87 $ 244.466  Millions$ 11.180  Millions
Eledon Pharmaceuticals Inc   21.73 $ 62.991  Millions$ 2.899  Millions
Astria Therapeutics inc   21.53 $ 191.466  Millions$ 8.894  Millions
Xenon Pharmaceuticals Inc   21.46 $ 531.008  Millions$ 24.744  Millions
Sagimet Biosciences inc   20.79 $ 102.816  Millions$ 4.946  Millions
Acasti Pharma Inc   20.68 $ 28.887  Millions$ 1.397  Millions
Akero Therapeutics Inc   20.25 $ 575.979  Millions$ 28.447  Millions
Tenax Therapeutics Inc   19.73 $ 11.883  Millions$ 0.602  Millions
Mineralys Therapeutics Inc   19.59 $ 265.375  Millions$ 13.543  Millions
Pliant Therapeutics Inc   19.50 $ 534.335  Millions$ 27.395  Millions
Stoke Therapeutics Inc   19.47 $ 230.019  Millions$ 11.811  Millions
Eqrx Inc   19.38 $ 1,235.139  Millions$ 63.726  Millions
Ideaya Biosciences Inc   19.37 $ 482.182  Millions$ 24.893  Millions
Pmv Pharmaceuticals Inc   19.16 $ 205.296  Millions$ 10.716  Millions
Savara Inc   18.98 $ 170.096  Millions$ 8.963  Millions
Medicinova Inc   18.92 $ 52.996  Millions$ 2.802  Millions
Immuneering Corporation  18.90 $ 100.583  Millions$ 5.321  Millions
Nextcure Inc   18.72 $ 122.684  Millions$ 6.552  Millions
Fulcrum Therapeutics Inc   18.65 $ 262.490  Millions$ 14.075  Millions
Compass Pathways Plc  18.55 $ 284.806  Millions$ 15.350  Millions
Edgewise Therapeutics inc   18.23 $ 297.921  Millions$ 16.338  Millions
Keros Therapeutics Inc   18.23 $ 304.435  Millions$ 16.701  Millions
89bio Inc   18.23 $ 459.526  Millions$ 25.212  Millions
Trevi Therapeutics Inc   18.16 $ 93.953  Millions$ 5.173  Millions
Kura Oncology Inc   17.80 $ 459.917  Millions$ 25.843  Millions
Olema Pharmaceuticals inc   17.66 $ 282.008  Millions$ 15.966  Millions
Briacell Therapeutics Corp   17.59 $ 18.408  Millions$ 1.047  Millions

Date modified: 2023-11-08T19:21:33+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com